Aruni Ghose: Externally validating the Meet-URO Novel Prognostic Score in MRCC on First Line Immuno Combination Therapies

Aruni Ghose shared on LinkedIn:

“Externally validating the Meet-URO Novel Prognostic Score in Metastatic Renal Cell Cancer on First Line Immuno Combination Therapies – has to be the most successful Real World Evidence venture I have undertaken in my 4 years of being a doctor driven for passion in Cancer RWE generation.

I attended the first International Urology Cancer Summit 2023 and saw Sara Elena Rebuzzi presenting the Italian Internal Validation – Beginning 2024 I told her ‘Let us change history with the changed landscape’.

6 months later – I had recruited centres from the UK, Turkey, Hong Kong to make a total of 27.

Boasts of a ‘HIGHER PREDICTIVE ACCURACY THAN IMDC’ with 2 additional predictive factors.

This was such great Teamwork, Network creation, and more importantly CLINICAL PRACTICE GUIDELINE changing RWE generation – Best Abstract at IUCS24.”

Source: Aruni Ghose/LinkedIn

For more posts by Aruni Ghose, visit oncodaily.com

Aruni Ghose, an Internal Medicine Resident at Barts Health NHS Trust, holds a council position in the Oncology Section at the Royal Society of Medicine. Additionally, he serves as a Focused Topic Network Member at the European Cancer Organisation and sits on the Editorial Board at BMC. His research focuses on Genitourinary Cancer, Immuno Oncology, Global Oncology, Cardio Oncology, and Lung Cancer.